ACRX
AcelRx
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 131.87M; Volume: 284.13K; AvgVol 3m: 1.49M; Beta: 1.68;
Cost estimate:
P/E: –; EPS: -0.62; EPS growth quarter/prev quarter: 47.90%;
EPS growth this year: 16.70%; EPS growth past 5 years: 2.60%;
EPS ttm: -0.62;
P/S: 27.30; P/B: ; P/Cashflow: 2.75; P/FCF: ;
Sales: 4.39M; Sales growth quarter/prev quarter: 222.20%; Sales growth past 5 years: -15.20%;
Profitability:
Gross Margin: -51.30%; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -58.30%; ROE – return on equity: 107.40%; LT Debt/Equity: ; Total Debt/Equity: ;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 1.10%; Insider Transactions:0.77%;
Institutional Ownership: 20.00%; Institutional Transactions: -5.56%;
Data update: 07.10.2020.